Earnings Call Summary | NRX Pharmaceuticals(NRXP.US) Q1 2024 Earnings Conference
Earnings Call Summary | NRX Pharmaceuticals(NRXP.US) Q1 2024 Earnings Conference
The following is a summary of the NRx Pharmaceuticals, Inc. (NRXP) Q1 2024 Earnings Call Transcript:
以下是NRx製藥公司(NRXP)2024年第一季度業績電話會議記錄摘要:
Financial Performance:
財務業績:
NRx Pharmaceuticals reported a Q1 2024 net loss of $6.5 million, a reduction of 41% year over year.
Research and development expenses dropped from $3.7 million in Q1 2023 to $1.7 million in Q1 2024.
General and administrative expenses decreased by 26% from $5.8 million in Q1 2023 to $4.3 million in Q1 2024.
The company's working capital improved by $8 million due to equity sales and an Alvogen milestone advance, and corporate debts were reduced by $2.2 million.
nRx Pharmicals報告稱,2024年第一季度淨虧損650萬美元,同比下降41%。
研發費用從2023年第一季度的370萬美元下降到2024年第一季度的170萬美元。
一般和管理費用從2023年第一季度的580萬美元下降到2024年第一季度的430萬美元,下降了26%。
由於股權出售和Alvogen的里程碑式進展,該公司的營運資金增加了800萬美元,公司債務減少了220萬美元。
Business Progress:
業務進展:
NRx Pharmaceuticals plans to file two new drug applications for NRX-101, used in the treatment of suicidal bipolar depression, chronic pain, and also shows antibacterial effects against dangerous urinary pathogens.
The Company aims to make a transition from a purely research and development focus to a revenue-generating company by 2024 and is exploring potential treatments for schizophrenia.
NRx is also developing 'HTX-100', an IV ketamine treatment for suicidal depression and exploring partnership opportunities to expand its market presence.
Further business progress includes plans to separate from their current lender to reduce debt costs and improve shareholder benefits.
nRx Pharmicals計劃申請兩種 NRX-101 新藥,用於治療自殺性雙相抑鬱症、慢性疼痛,還顯示出對危險尿路病原體的抗菌作用。
該公司的目標是到2024年從純粹的研發重點過渡到創收公司,並正在探索精神分裂症的潛在治療方法。
nRx 還在開發 “HTX-100”,一種治療自殺抑鬱症的靜脈****療法,並探索合作機會以擴大其市場佔有率。
進一步的業務進展包括計劃與目前的貸款機構分離,以降低債務成本和改善股東利益。
More details: NRX Pharmaceuticals IR
更多詳情: NRX 製藥 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。
譯文內容由第三人軟體翻譯。